Mauro Tambasco

Dr. Mauro Tambasco

Physics, San Diego State University, San Diego, California, USA
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DSDavid A. Steinman
David A. Steinman
TPTamie L. Poepping
Tamie L. Poepping
Mauro TambascoMauro Tambasco
Mauro Tambasco
RRRichard N. Rankin
Richard N. Rankin
DHDavid W. Holdsworth
David W. Holdsworth

31 December 2010 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Mauro TambascoMauro Tambasco
Mauro Tambasco
MEMisha Eliasziw
Misha Eliasziw
AMAnthony M Magliocco
Anthony M Magliocco
Precise criteria for optimal patient selection for adjuvant chemotherapy remain controversial and include subjective components such as tumour morphometry (pathological grade). There is a need to replace subjective criteria with objective measurements to improve risk assessment and therapeutic decisions. We assessed the prognostic value of fractal dimension (an objective measure of morphologic complexity) for invasive ductal carcinoma of the breast.

1 October 2003 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
Mauro TambascoMauro Tambasco
Mauro Tambasco
DSDavid A. Steinman
David A. Steinman

14 September 2011 in Medical Physics
Verified
Journal Article
Closed access
MNMarcel Nauta
Marcel Nauta
JVJ. Eduardo Villarreal-Barajas
J. Eduardo Villarreal-Barajas
Mauro TambascoMauro Tambasco
Mauro Tambasco

3 February 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
APAlan Perstin
Alan Perstin
YPYannick Poirier
Yannick Poirier
ASAmit Sawant
Amit Sawant
Mauro TambascoMauro Tambasco
Mauro Tambasco
To investigate a plasmid DNA nicking assay approach for isolating and quantifying the DNA-damaging effects of ultrahigh-dose-rate (ie, FLASH) irradiation relative to conventional dose-rate irradiation. We constructed and irradiated phantoms containing plasmid DNA to nominal doses of 20 Gy and 30 Gy using 16 MeV electrons at conventional (0.167 Gy/s) and FLASH (46.6 Gy/s and 93.2 Gy/s) dose rates. We delivered conventional dose rates using a standard clinical Varian iX linear accelerator and FLASH dose rates (FDRs) using a modified Varian 21EX C-series linear accelerator. We ran the irradiated DNA and controls (0 Gy) through an agarose gel electrophoresis procedure that sorted and localized the DNA into bands associated with single strand breaks (SSBs), double strand breaks (DSBs), and undamaged DNA. We quantitatively analyzed the gel images to compute the relative yields of SSBs and DSBs and applied a mathematical model of plasmid DNA damage as a function of dose to compute the relative biological effectiveness (RBE) of SSB and DSB (RBESSB and RBEDSB) damage for a given endpoint and FDR. Both RBESSB and RBEDSB were less than unity with the FDR irradiations, indicating FLASH sparing. With regard to the more deleterious DNA DSB damage, the DSB RBEs of FLASH beams at dose rates of 46.6 Gy/s and 93.2 Gy/s relative to the conventional 16 MeV beam dose rate were 0.54 ± 0.15 and 0.55 ± 0.17, respectively. This study demonstrated the feasibility of using a DNA-based phantom to isolate and assess the FLASH sparing effect on DNA. We also found that FLASH irradiation causes less damage to DNA compared with a conventional dose rate. This result supports the notion that the protective effect of FLASH irradiation occurs at least partially via fundamental biochemical processes.

1 May 2008 in Human Pathology
Verified
Journal Article
Closed access
Mauro TambascoMauro Tambasco
Mauro Tambasco
AMAnthony M. Magliocco
Anthony M. Magliocco